NewsBenzingaArmata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02 Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02 Benzinga 2026.09.23 11:09 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on PENN Entertainment, Lowers Price Target to $22 HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target Alphabet Stock Rises: What's Going On? $1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today Wells Fargo Maintains Equal-Weight on MGM Resorts International, Lowers Price Target to $29 Why Is Applied Digital Stock Surging on Monday?
